Sentences with phrase «treatments enzalutamide»

Leigh Ellis, PhD, and colleagues at Roswell Park Comprehensive Cancer Center (Roswell Park) have identified two genes that appear to be simultaneously overexpressed in aggressive prostate cancers resistant to the androgen - targeted treatments enzalutamide and abiraterone acetate.

Not exact matches

Several clinical centres in the USA and Canada recruited four groups of men with CRPC to a phase II study to receive 2550 mg of galeterone orally once a day: 22 men had CRPC that had not metastasised (spread) and had received no previous treatment; 39 men had metastatic CRPC and no previous treatment with abiraterone or enzalutamide; 37 and nine men had metastatic CRPC and had failed treatment with abiraterone and enzalutamide respectively.

«Recent data have shown that a variant of the androgen receptor called AR - V7, found in tumour cells circulating in the blood of patients with metastatic CRPC, predicted resistance to treatment with enzalutamide and abiraterone,» she will say.

Among the group of men who had non-metastatic and metastatic disease who had not received prior treatment with abiraterone and enzalutamide, data for 60 were available for analysis.

Enzalutamide, which is taken as four pills once per day, is already approved by the Food and Drug Administration (FDA) for men whose disease has not been stopped by other treatments including, surgery, radiation, androgen deprivation therapy and chemotherapy.

The strong response to this new use of enzalutamide shows that it can provide a viable, less toxic alternative to chemotherapy in staving off the disease in men who aren't responding to standard first line hormonal treatments,» said Tomasz Beer, M.D., the lead author on the study and deputy director of the Knight Cancer Institute at OHSU.

While the outlook of patients with this gene variant is poor, these studies offer hope for a new treatment strategy for these men, and more studies are needed using next - generation androgen inhibitors, such as abiraterone and enzalutamide.

Subjects must have progressed on prior new hormonal agent (e.g. abiraterone acetate and / or enzalutamide) for the treatment of mCRPC.

A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration - Resistant Prostate Cancer who have Failed Prior Treatment with a New Hormonal Agent and have Homologous Recombination Repair Gene Mutations.

Abiraterone / prednisone and enzalutamide are both first - line therapies for treatment of metastatic CRPC but no trials to date have compared them head to head.